Chinolizinium | 255-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: Chinolizinium
• 英文别名: Quinolizinium；quinolizin-5-ium
• CAS: 255-59-4
• 化学式: C₉H₈N
• 分子量: 130.169
• InChiKey: GUOHRXPYGSKUGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  4.1
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• [EN] 3- `4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS<br/>[FR] 3- `4- {ALKANOYLE SUBSTITUÉ EN POSITION 6) PYRIDIN-3-YL} -3-PHÉNYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMÉTHYL) -1, 3-OXAZOLIDIN-2-ONES UTILISÉS EN TANT QU'AGENTS ANTIBACTÉRIENS
  申请人：ASTRAZENECA AB

  公开号：WO2005116022A1

  公开（公告）日：2005-12-08

  Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.

  公式（I）的化合物以及其药用可接受的盐和前药已被披露，其中R1、R2、R3和R4在此处被定义。还披露了制备公式（I）化合物的方法，以及使用公式（I）化合物治疗细菌感染的方法。
• [EN] DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS<br/>[FR] DIMÈRES DE MOLÉCULES BIOACCESSIBLES EN TANT QUE COPOLYMÈRES
  申请人：ZYMERGEN INC

  公开号：WO2022006023A1

  公开（公告）日：2022-01-06

  The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids or hydroxy acids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer or a hydroxy acid dimer.

  本公开涉及源自生物可达分子的组合物，例如氨基酸或羟基酸。具体而言，该组合物可以是源自氨基酸二聚体或羟基酸二聚体的单体、聚合物或共聚物。
• 2-PHENYL-6-AZOLYLPYRIDINE-BASED LIGAND AND GROUP VIII TRANSITION METAL COMPLEX
  申请人：Chi Yun

  公开号：US20130018189A1

  公开（公告）日：2013-01-17

  A 2-phenyl-6-azolylpyridine-based ligand is represented by the following formula (I): wherein, X represents nitrogen or C—R 10 ; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 10 independently represent hydrogen, halogen, a cyano group, an amino group, an optionally substituted aryl group, an optionally substituted heteroaryl group, sulfate, —COOH, an alkoxy group, a carbonyl group, a C 1 -C 10 haloalkyl group, a C 1 -C 12 alkyl group, a C 2 -C 10 alkenyl group, a C 2 -C 10 alkynyl group, a C 3 -C 20 cycloalkyl group, a C 3 -C 20 cycloalkenyl group, a C 1 -C 20 heterocycloalkyl group, or a C 1 -C 20 heterocycloalkenyl group; and R 9 represents hydrogen or alkali metal.

  一种基于2-苯基-6-氮杂吡啶的配体由以下公式（I）表示：其中，X代表氮或C—R10；R1、R2、R3、R4、R5、R6、R7、R8和R10独立地代表氢、卤素、氰基、氨基、可选择取代的芳基、可选择取代的杂环芳基、硫酸根、—COOH、烷氧基、羰基、C1-C10卤代烷基、C1-C12烷基、C2-C10烯基、C2-C10炔基、C3-C20环烷基、C3-C20环烯基、C1-C20杂环烷基或C1-C20杂环烯基；R9代表氢或碱金属。
• [EN] CARBON MONOXIDE-RELEASING MOLECULES TRIGGERED BY PHYSIOLOGICAL STIMULI<br/>[FR] MOLÉCULES À LIBÉRATION DE MONOXYDE DE CARBONE DÉCLENCHÉE PAR DES STIMULI PHYSIOLOGIQUES
  申请人：UNIV GEORGIA STATE RES FOUND

  公开号：WO2019032879A1

  公开（公告）日：2019-02-14

  The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.

  本发明一般涉及一氧化碳释放化合物和组合物，以及它们作为一氧化碳前药的用途。
• Use of benzo[c]quinolizinium derivatives for the treatment of diseases that are linked to smooth muscle cell constriction
  申请人：Becq Frederic

  公开号：US20050176747A1

  公开（公告）日：2005-08-11

  The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.

  该发明涉及使用苯并[c]喹啉衍生物治疗与平滑肌细胞收缩有关的疾病，如高血压和哮喘。